Cardiology: Clinical Research Program

Banner

Cardiology: Clinical Studies Open For Enrollment

 

PROTOCOL CY 6031 A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF CK3773274 IN ADULTS WITH SYMPTOMATIC HYPERTROPHIC CARDIOMYOPATHY AND LEFT VENTRICULAR OUTFLOW TRACT OBSTRUCTION

Eligibility

  • Symptomatic Hypertrophic cardiomyopathy
  • Hemoglobin at least 10 g/dL at screening
  • No moderate-severe valvular aortic stenosis and/or regurgitation

Enrollment Status: Enrolling

Study Information

ClinicalTrials.gov | NCT05186818

Principal Investigator

Dr. Srihari Naidu

Contact for Study Screening

Erida.Castro@wmchealth.org and FNU.Namrata@wmchealth.org

 

PROTOCOL CY 6022 AN OPEN-LABEL STUDY OF CK3773274 FOR PATIENTS WITH SYMPTOMATIC HYPERTROPHIC CARDIOMYOPATHY (HCM)

Eligibility

  • Symptomatic Hypertrophic cardiomyopathy
  • Any acute or serious comorbid

Enrollment Status: Enrolling

Study Information

ClinicalTrials.gov | NCT04848506

Principal Investigator

Dr. Srihari Naidu

Contact for Study Screening

Erida.Castro@wmchealth.org and FNU.Namrata@wmchealth.org

 

Observational Study Protocol CV027-012 DELIVER INSIGHTS IN HYPERTROPHIC CARDIOMYOPATHY AND OBSERVATIONAL OUTCOMES IN REAL WORLD (DISCOVER-HCM): UNITED STATES PROSPECTIVE REGISTRY STUDY

Eligibility

  • Diagnosis of obstructive Hypertrophic cardiomyopathy

Enrollment Status: Enrolling

Study Information

ClinicalTrials.gov | NCT05489705

Principal Investigator

Dr. Srihari Naidu

Contact for Study Screening

Erida.Castro@wmchealth.org and FNU.Namrata@wmchealth.org

 

A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein (a)

Eligibility

  • Atherosclerotic Cardiovascular Disease by the history of either Myocardial infarction or Coronary revascularization.
  • No severe renal dysfunction.

Enrollment Status: Enrolling

Study Information

ClinicalTrials.gov | NCT05581303

Principal Investigator

Dr. Diwakar Jain

Contact for Study Screening

Erida.Castro@wmchealth.org and FNU.Namrata@wmchealth.org

 

A multi-center, randomized, double-blind, placebo-controlled, parallel-group Phase IIIb study evaluating the effect of inclisiran on atherosclerotic plaque progression assessed by coronary computed tomography angiography (CCTA) in participants with a diagnosis of non-obstructive coronary artery disease without previous cardiovascular events (VICTORION-PLAQUE).

Eligibility

  • Male or female ≥18 years or ≤80 years of age
  • Fasting LDL-C local lab value at the Screening Visit of either i) ≥100 mg/dL.
  • Presence of coronary artery plaque with visual diameter stenosis <50% or Coronary artery plaque with visual artery stenosis >50% by (CCTA or coronary angiography).
  • Participants must be on a stable (≥4 weeks) dose of maximally tolerated statin therapy.
  • No previous cardiovascular events history including myocardial infarction (MI), nor prior coronary revascularization [percutaneous coronary intervention (PCI), nor coronary artery bypass graft (CABG)]; No uncontrolled severe hypertension either Heart failure New York Heart Association (NYHA) class III or class IV.

Enrollment Status: Enrolling

Study Information

ClinicalTrials.gov | NCT05360446

Principal Investigator

Hasan Ahmad, MD

Contact for Study Screening

FNU.Namrata@wmchealth.org

 

A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adults with Symptomatic Non-obstructive Hypertrophic Cardiomyopathy

Eligibility

  • Male or female at least 18 years of age
  • Diagnosis of HCM- hypertrophic cardiomyopathy
  • New York Heart Association (NYHA) Class II or III
  • CPET: Documented oxygen saturation at rest > 90% at screening

Enrollment Status: Enrolling

Principal Investigator

Srihari Naidu, MD

Study Information

ClinicalTrialsRegister.eu | 2021-005329-26

Contact for Study Screening

FNU.Namrata@wmchealth.org

 

Sponsor-Initiated OCS Heart Perfusion (OHP-II) Registry

Eligibility

  • Male or female at least18 years of age
  • All heart transplant recipients who are transplanted with an Organ Care System (OCS) perfused donor heart are eligible for this registry.

Enrollment Status: Enrolling

Principal Investigator

Suguru Ohira, MD

Study Information

ClinicalTrials.gov | NCT05915299

Contact for Study Screening

Corazon.DeLaPena@wmchealth.org